Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 58 of 6381 for:    zero

Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety ([11C]Butanol)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04050800
Recruitment Status : Not yet recruiting
First Posted : August 8, 2019
Last Update Posted : August 8, 2019
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
This will be a Phase 1, open label, imaging study of radiochemical and radiation safety in healthy volunteers. Using positron emission tomography (PET) and in-line computed tomography (CT), the whole body (WB) biokinetics of Carbon-11 butanol will be quantified with serial scans acquired every 3 minutes for two hours. Vital signs (VS), electrocardiograms (ECGs) and clinical laboratory tests of intrernal organ function will be acquired before and at several timepoints after administration of the radiopharmaceutical. Radiation exposures will be estimated with the MIRD Formalism.

Condition or disease Intervention/treatment Phase
Neuro-Degenerative Disease Drug: Carbon 11 Butanol Early Phase 1

Detailed Description:
Vital signs (VSs) will be measured, electrocardiograms (ECGs) will be acquired, and blood will be sent to the clinical laboratory for safety assessments before a single dose, intravenous (IV) administration of 555 MBq of Carbon-11 butanol. VSs will be re-measured, ECGs will be acquired again, and more blood will be sent to the clinical laboratory for repeat safety assessments after 2 hours of whole body (WB) scanning. WB scanning will consist of imaging acquisition sweeps of 200 cm from head-to-toe over 180 secs (3 min). Up to 40 sweeps per imaging session will be performed. The subjects will then be given a rest period ("coffee break") for about two hours, after which the entire sequence of events will be repeated. The primary outcome measure will be related to radiation safety derived from the areas under the time-activity curves (AUCs) for internal organs. Co-primary clinical safety measures will include changes in VSs, ECG parameters such as the PR and corrected QT intervals, and clinical laboratory tests, such as proteins that reflect renal and hepatic function. Secondary endpoints will include the time-activity curves (TACs) and total volumes of distribution (VT) in several brain regions. The results should allow calculation of the repeatability coefficients (RCs) under zero-biological-change conditions. RC values will be essential for understanding whether future measurements of effect sizes in response to therapeutic maneuvers or the differences between groups are meaningful.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Characterizing the Safety of [Carbon-11]Butanol and Estimating the Test-Retest Variance in Measurements of Its Whole Body Biokinetics Under Zero-Biological-Change Conditions
Estimated Study Start Date : September 2019
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Healthy Controls
Subjects will be administered two sequential doses of the radiopharmaceutical under nearly zero-biological-change conditions.
Drug: Carbon 11 Butanol
Two sequential administrations of a PET tracer
Other Name: [11C]Butan-1-Ol




Primary Outcome Measures :
  1. Effective Dose (ED) [ Time Frame: Day 1, from the measurements of exposures during the first 2 hours post administration. ]
    Fundamental radiation dose quantity in the International Commission on Radiological Protection (ICRP) system of radiological protection. Calculated with OLINDA-EXM software (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling).


Secondary Outcome Measures :
  1. Change in Radiochemical Safety Assessments [ Time Frame: Pulse at two hours post administration compared to pulse shortly before administration. ]
    Change in pulse

  2. Change in Radiochemical Safety Assessments [ Time Frame: Blood pressure at two hours post administration compared to blood pressure shortly before administration. ]
    Change in blood pressure

  3. Change in Radiochemical Safety Assessments [ Time Frame: At two hours post administration compared to same parameters shortly before administration. ]
    Change in heart rhythm on electrocardiogram (ECG)

  4. Change in number of Subjects with prolonged PR interval greater than 20 mSec [ Time Frame: At two hours post administration compared to same parameters shortly before administration. ]
    Change in PR interval on electrocardiogram (ECG)

  5. Change in number of subjects with QTc >440 mSec [ Time Frame: At two hours post administration compared to same parameters shortly before administration. ]
    Change in corrected QT interval on electrocardiogram (ECG).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • able to give informed consent.
  • age 18-89
  • Subjectively healthy and, in the opinion of the investigators, likely to tolerate the imaging procedures and be compliant with the schedule of follow up telephone calls.
  • Normal hemodynamic function. Systolic blood pressure and pulse must be higher than 120 mmHg and 60 beats per minute while sitting. At the discretion of the investigators, people who regularly engage in vigorous exercise more than four times per week may be enrolled if their systolic blood pressure and pulse are higher than 100 mmHg and 50 beats per minute while sitting.
  • Unremarkable electrocardiograms, with PR intervals of less than 200 mSec and QTcF intervals (corrected with Frederica's method) of less than 440 mSec.
  • No concurrent medications with the exception of p.r.n. NSAIDS, which must be discontinued one week prior to PET scanning.
  • Willing and able to refrain from abusing any recreational drugs, including marijuana, and drink less than one unit of alcoholic beverages per day starting one week prior to PET scanning, and avoided for the next four weeks.
  • Willing to refrain from donating blood for four (4) weeks before the study and for four (4) weeks after the study.
  • Willing to refrain from participating in any other research study that requires taking medication for four (4) weeks before the study and for four (4) weeks after the study.
  • Willing to refrain from being vaccinated for four (4) weeks before the study and for four (4) weeks after the study.
  • All clinical laboratory test results within normal limits or not clinically significant. For example, elevated bilirubin levels in subjects with Gilbert's syndrome will be allowed, as will small red blood cell volumes in healthy people with sickle cell trait.

Exclusion Criteria:

  • Subjects may not be a member of a vulnerable population.
  • Women may not be pregnant or breast feeding.
  • History of multiple hypersensitivity reactions (atopia), as indicated by allergies to multiple medications, foods, and seasonal pollens.
  • History, physical examination, or clinical laboratory tests suggestive of a condition, disorder, or disease that could adversely affect drug absorption, distribution, metabolism, or elimination (ADME) of the tracer, including chronic liver or renal failure.
  • Positive urine toxicology screen for recreational drugs other than marijuana.
  • May not have taken any controlled medications, including other study drugs, in the 30 days prior to PET scanning or for 10 half-lives, whichever is longer.
  • May not have donated blood in the 30 days prior to PET scanning.
  • May not have participated in research administering drugs in the last 30 days.
  • May not have been vaccinated in the 30 days prior to PET scanning.
  • May not have been exposed to radiation during research of more than 10 mSv during the last year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04050800


Contacts
Layout table for location contacts
Contact: P. David Mozley, MD 212 746 5805 dvm9029@med.cornell.edu
Contact: Jamie Stern, MS 212 746 9748 jas2071@med.cornell.edu

Locations
Layout table for location information
United States, New York
Weill Cornell Medicine
New York, New York, United States, 10065
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Layout table for investigator information
Principal Investigator: P. David Mozley, MD Cornell University Weill College of Medicine

Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT04050800     History of Changes
Other Study ID Numbers: 19-05020069
First Posted: August 8, 2019    Key Record Dates
Last Update Posted: August 8, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All de-identified data will be shared. The investigators will attempt to contribute the "raw" imaging data to a public archive for curation.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Upon publication of the results.
Access Criteria: Any investigators with a reasonable request for the data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neurodegenerative Diseases
Nervous System Diseases